WSU researchers assess use of cannabis in treating stress, anxiety and depression Using Strainprint Technologies Ltd. Data

PULLMAN, WA – In a first-of-a-kind study, Washington State University scientists examined how peoples’ self-reported levels of stress, anxiety and depression were affected by smoking different strains and quantities of cannabis at home.

Their work, published this month in the Journal of Affective Disorders, suggests smoking cannabis can significantly reduce short-term levels of depression, anxiety, and stress but may contribute to worse overall feelings of depression over time.

It marks one of the first attempts by U.S. scientists to assess how cannabis with varying concentrations of the chemical compounds tetrahydrocannabinol (THC) and cannabidiol (CBD) affect medicinal cannabis users’ feelings of well-being when smoked outside of a laboratory.

“Existing research on the effects of cannabis on depression, anxiety and stress are very rare and have almost exclusively been done with orally administered THC pills in a laboratory,” said Carrie Cuttler, clinical assistant professor of psychology at WSU and lead author of the study. “What is unique about our study is that we looked at actual inhaled cannabis by medical marijuana patients who were using it in the comfort of their own homes as opposed to a laboratory.”

For example, the WSU research team found that one puff of cannabis high in CBD and low in THC was optimal for reducing symptoms of depression, two puffs of any type of cannabis was sufficient to reduce symptoms of anxiety, while 10 or more puffs of cannabis high in CBD and high in THC produced the largest reductions in stress.

“A lot of consumers seem to be under the false assumption that more THC is always better,” Cuttler said. “Our study shows that CBD is also a very important ingredient in cannabis and may augment some of the positive effects of THC.”

The researchers also found that while both sexes reported decreases in all three symptoms after using cannabis, women reported a significantly greater reduction in anxiety following cannabis use.

Data for the study were taken from the trademarked app Strainprint, which provides medical cannabis users a means of tracking how different doses and types of cannabis affect a wide variety of symptoms of well-being.

Strainprint users rate the symptoms they are experiencing before using cannabis on a scale of 1-10 and then input information about the type of cannabis they are using. Twenty minutes after smoking, they are prompted to report how many puffs they took and to re-rate the severity of their symptoms.

Cuttler and WSU colleagues Alexander Spradlin and Ryan McLaughlin used a form of statistical analysis called multilevel modeling to analyze around 12,000 anonymous Strainprint entries for depression, anxiety and stress. The researchers did not receive any of the Strainprint users personally identifying information for their work.

“This is to my knowledge one of the first scientific studies to provide guidance on the strains and quantities of cannabis people should be seeking out for reducing stress, anxiety and depression,” Cuttler said. “Currently, medical and recreational cannabis users rely on the advice of bud tenders whose recommendations are based off of anecdotal not scientific evidence.”

The study is among several cannabis-related research projects currently underway at WSU, all of which are consistent with federal law and many of which are funded with Washington state cannabis taxes and liquor license fees.

A list of those research projects is available at https://news.wsu.edu/2018/04/18/wsu-researchers-focusing-range-cannabis-health-issues/.

For more information contact:
Jessica Moran
Director, Marketing & Communications
(519) 494-5379
jessica.moran@strainprint.ca

Strainprint™ Technologies Ltd. (“Strainprint”) Launches its Strainprint Analytics Business Intelligence Platform

PRESS RELEASE: 

TORONTO, March 28, 2018 /CNW/ – Strainprint, the leader in cannabis data collection and strain efficacy reporting, is thrilled to announce the launch of Strainprint Analytics, a powerful web-based data platform for visually mining the world’s largest data set on strain efficacy and real-time patient use. On March 27, Strainprint gathered with key Members of Parliament, Health Canada and cannabis industry leaders at the Rideau Club in Ottawa for the launch of Strainprint Analytics to demonstrate Strainprint’s ability to support public policy for both medical and recreational cannabis use across North America, based on factual data and analytics.

The Strainprint Ecosystem starts with its renowned mobile journaling app where tens of thousands of patients have tracked almost 400,000 medical records from lab-verified strains generating 6 million data points on cannabis strain efficacy. Strainprint Analytics is the ground-breaking, web data platform for real-time, visual insight into the aggregate and anonymized data.

Strainprint Analytics is available by subscription in 2 editions: The Producer Edition is for growers and retailers and provides market intelligence and decision support tools for optimizing production and rewarding engaged customers; The Clinic Edition is for clinicians, health practitioners and researchers, delivering treatment guidance tools that help maximize clinic throughput and profitability. It’s also the place where subscribers can conduct targeted clinical research by specific symptom or cohort.

“We are beyond excited to launch the Strainprint Analytics data platform”, said Dave Berg, President & CTO of Strainprint. “Our development team has been working diligently over the last 6 months to deliver this first-of-its-kind tool to the Cannabis Industry. We look forward to continuing to support licensed producers, clinics, retailers, pharmacies and government with real-time decision support tools, while continuing to help thousands of ACMPR patients to lead healthier lives.”

“We were so pleased to be joined last night by esteemed members of government and Industry leaders to celebrate this important company and industry milestone.” Added Andrew Muroff, CEO of Strainprint.

About StrainprintTM:
Founded in Toronto in 2016,StrainprintTM Technologies Ltd. is the leading demand-side cannabis data and analytics company, gathering real-time cannabis consumption and efficacy data on lab-verified strains. StrainprintTM data supports global cannabis research and provides advanced business intelligence and treatment guidance to producers, retailers, medical practitioners, pharma, government and industry. Strainprint is HIPAA, PIPEDA and PHIPA privacy compliant, military-grade encrypted and all patient data is completely anonymized and at rest in Canada. Strainprint can be seamlessly embedded or integrated with most electronic medical records (EMR) and seed2sale software systems. Strainprint Analytics is accessed by customer subscription. The Strainprint App is free to patients and can be downloaded from both the iOS App Store and GooglePlay Store. www.strainprintanalytics.com. facebook, twitter, linkedin

For further information: Media Contact: Jessica Moran, Strainprint™ Technologies Ltd., Jessica.moran@strainprint.ca, 519-494-5379

Strainprint Featured in The Leaf Cannabis News: Finding the right stuff Cannabis-tech firms’ experience-based apps help medical and recreational users through the confusing maze of strains and their effects

 

03/15/2018 – Strainprint was recently featured In The Leaf Cannabis News Where our President, David Berg discussed Cannabis Tech-Apps.

Berg says Strainprint has “over six million data points collected and over 300,000 validated sessions,” describing that database as “the largest longitudinal study on cannabis in the world.” He says that information can address the dearth of knowledge about the medical effects of cannabis. – Solomon Israel, The Leaf Cannabis News 

 

Strainprint Technologies Ltd. Is Pleased to Welcome Ashleigh Brown as Community Manager & Patient Liaison As The Team Continues To Expand

Strainprint is proud to announce our latest member of the Strainprint team, Ashleigh Brown. Ashleigh has come on board to be Strainprint’s Community Manager and Patient Liaison.

Ashleigh’s own journey as a medical cannabis patient as well as the Founder of SheCann: Legal Medical Cannabis Empowering Canadian Women gives her the unique opportunity to deepen the connections she has with fellow patients, as well as channel her empathy, love of learning and all things data into helping patients use cannabis better, and mindfully medicate.

Q: When and why did you start using medical cannabis?

A: I received my medical cannabis prescription in August 2016. I started using medical cannabis as a last resort, really. In 2009, I began having seizures, and by 2016 I had exhausted all of my medical options. At my worst point, I was having 150-180 events per month. I had the cognitive functioning of a 70-year-old with senile dementia. Using medical cannabis has changed all of that. I still have seizures, but they no longer number in the hundreds. I have around 12-15 per month now. I am able to care for my daughters, attend their school events, and I am able to work again.

Q: What are you passionate about?

A: I start every morning with the same few words to myself: ‘let me be of service to people in the ways they need me’. I am passionate about helping people, and what I have learned is that at the core of so much of our human experience is a need to just feel seen. I am passionate about serving people, and I am humbled to be able to do so during some of their darkest and most challenging times.

Q: What do you like to do in your spare time?

A: I have always been a voracious reader. My nightstand is never without a stack of novels and works of non-fiction, and my Kobo goes with me everywhere. Words are some of my favourite things. I also love to spend time outside with my partner and my two daughters: last year my partner and I purchased a tandem bike, so we could hit the open road together…and embarrass the kids!

Q: What has been a defining moment for you thus far on your medical cannabis journey?

A: I began using medical cannabis at the suggestion of my best friend. Frankly, my first reaction was a bit dismissive. I had used it recreationally and it hadn’t helped. She told me to ‘forget everything I thought I knew about marijuana’. It was the best advice anyone could have given me, and it is the same advice I now give to others every day. Making the mental shift from ‘recreation’ to ‘medication’ is something that happened as a result of that support.

Q: What is the more unexpected thing you’ve encountered along your journey?

A: The biggest surprise in all of this, especially since I began my journey as an advocate, is how many people have these amazing stories of recovery, healing and hope. I am happy to say that my story is not unique: it is one of thousands of accounts of how using medical cannabis has improved and changed lives.

Q: What would you say to your younger/less experienced self?

A: “It gets better.” I love being in my thirties, because enough time has passed that I understand that life happens, but we can and do grow through the challenges. If my younger self was open to listening, I would remind her, and really anyone else, that you have survived 100% of your days. That’s a perfect record.

Q: If you weren’t doing this and could do ANYTHING what would you be doing?

A: I am so happy with my life right now. This all feels like a perfect fit, for me, my family, and my purpose. I can’t imagine doing anything else. But if I had to choose? I think I would work at Best Friends Animal Sanctuary in Utah. I could scoop poop there for eternity. It is not only one of the most beautiful places on earth, the work that the staff and volunteers do is monumental.

Q: Talk about your involvement with SheCann and why it is such an important forum/platform

A: When I founded SheCann in June of 2017, myself and a handful of other female patients had no idea how it would all unfold. We started the community in order to have a safe space to ask questions, and access resources and support around medical cannabis, without the stigma.

SheCann is a special Canadian Facebook community. It defies the stereotypes of most social media groups. There is no negativity, or hostility. We welcome vulnerability, curiosity, and compassion. We are patient focused, but we also welcome and encourage members of the medical cannabis industry to join us; including Licensed Producers, and clinics. We work closely with groups like CFAMM on the issues that matter to us as patients.

Our members are committed to advocating for themselves and others, and as legalization approaches, we want to speak up on issues that affect our access to medication.

We are stronger together. It is amazing and so empowering to learn more about our medicine by sharing our experiences. There are no stupid questions, and there are no invalid perspectives.

Q: What awards has SheCann/Yourself received?

A: The team and I were blown away to receive 3rd place in the Best Social Media Account-Facebook category at the Canadian Cannabis Awards in November.

Q: What does your daily life look like, beyond work?

A: We have a really diverse and amazing blended family. My daughters are 9 and (almost) 13, I have three brilliant, compassionate and wonderful adult step kids who have equally wonderful partners and spouses, and we have two granddaughters who never fail to keep us all smiling.